401 related articles for article (PubMed ID: 19787197)
1. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH
Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
5. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
7. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
Singh N; Tamariz J; Chamorro G; Medina-Franco JL
Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805
[TBL] [Abstract][Full Text] [Related]
9. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad U; Abbas T; Dutta A
Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065
[TBL] [Abstract][Full Text] [Related]
10. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
11. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Istvan ES
Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
[TBL] [Abstract][Full Text] [Related]
12. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
13. Mode of interaction of beta-hydroxy-beta-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds.
Nakamura CE; Abeles RH
Biochemistry; 1985 Mar; 24(6):1364-76. PubMed ID: 3886005
[TBL] [Abstract][Full Text] [Related]
14. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
15. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
16. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
[TBL] [Abstract][Full Text] [Related]
17. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Blum CB
Am J Cardiol; 1994 May; 73(14):3D-11D. PubMed ID: 8198021
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
20. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
